Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

EIK1004

Small molecule · Inhibitor of PARP1

Phase 2 Most advanced trial
1 Registered trials

What is EIK1004?

EIK1004 is an orally bioavailable, CNS-active PARP1 inhibitor that selectively binds to and inhibits PARP1, preventing DNA repair via the base excision repair pathway. This enhances DNA strand breaks and genomic instability, promoting apoptosis. It is studied in advanced solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
PARP1
Mechanism
Inhibitor of PARP1
Pathways
base excision repair, DNA damage response, apoptosis
Therapy area
Oncology
In trials of
IBO
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06907043 Phase 1/2 Advanced Solid Tumors Recruiting IBO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid Tumors

Other drugs acting on PARP1

Niraparib FDA approved Olaparib FDA approved 2X-121 Phase 2 IMP1734 Investigational Senaparib Investigational Veliparib Phase 1

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.